Research programme: diabetes protein therapeutics - Five Prime Therapeutics

Drug Profile

Research programme: diabetes protein therapeutics - Five Prime Therapeutics

Alternative Names: FPT 038

Latest Information Update: 19 Jun 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Five Prime Therapeutics
  • Class Antibodies; Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Diabetes mellitus

Most Recent Events

  • 18 Jun 2012 No development reported - Preclinical for Diabetes mellitus in USA (Parenteral)
  • 22 Jun 2011 Research programme: diabetes mellitus therapeutics is no longer licensed to Pfizer worldwide
  • 08 Feb 2011 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top